Turna Ray

The company is offering combined germline and somatic cancer testing, and sharing patients' variants identified through that testing in a new research registry.

The Right Drug Dose Now Act seeks to address many of the barriers that have hindered integration of pharmacogenomic information into mainstream care.

The company believes the platform will expedite its longstanding goal of amassing genomic and other information from patients through their lifespan to fuel discoveries and improve care.

The company plans to launch a polygenic risk score, a germline-somatic test platform, and LDT and kitted tests for disease monitoring and therapy selection.

National Government Services' proposal to broaden coverage of large sequencing panels for solid tumor patients is positive but may need clarification to ensure appropriate patient care.

The EC has stuck with its timeline to implement the new regulations in eight months, raising concerns for cancer patients' ability to receive biomarker testing and treatments.

The law requires state employee, Medicaid, public school, and small employer plans to cover evidence-based biomarker testing, a change that will readily impact cancer patients.

The California health system is working with Canexia to assess if a triaged, in-house testing strategy improves outcomes, lowers cost, and reduces access inequities.

During an "Investor Day" presentation, company executives presented plans for growing test volumes, increasing market share, and expanding access to underserved populations.

Although the logistics still need to be worked out, the partners hope to streamline oncologists' experience ordering tests that can inform patient care.